Загрузка...
The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer
Lung cancer is the most common cancer and leading cause of cancer death. While targeted therapies have redefined treatment options for non-small cell lung carcinoma (NSCLC) with genetic aberrations such as epidermal growth factor and anaplastic lymphoma kinase, many patients do not harbour these onc...
Сохранить в:
| Опубликовано в: : | Ther Adv Med Oncol |
|---|---|
| Главные авторы: | , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
SAGE Publications
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6716180/ https://ncbi.nlm.nih.gov/pubmed/31497071 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835919870360 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|